Skip to main content

Table 3 NASH therapies in clinical trials

From: Nonalcoholic fatty liver disease and type 2 diabetes: where do Diabetologists stand?

  Description Target Phase Duration
Obeticholic acid Semisynthetic bile acid FXR agonist IIIa 72 weeks
Elafibranor Small-molecule Dual PPAR α/δ agonist III 72 weeks
Resmetirom Small-molecule THR β agonist III 52 weeks
Aramchol Synthetic FABAC SCD-1 modulator III 52 weeks
Cenicriviroc Small-molecule Dual CCR2/CCR5 antagonist III 48 weeks
  1. Abbreviations: NASH Nonalcoholic steatohepatitis, FXR Farnesoid x receptor, PPAR Peroxisome proliferator-activated receptor, THR Thyroid hormone receptor, FABAC Fatty-acid/bile-acid conjugate, SCD Stearoyl-CoA desaturase, CCR C-c chemokine receptor
  2. aTopline results demonstrated significant improvement in fibrosis by 1 stage in patients on OCA 25 mg daily compared to those in the placebo arm [103]